EU watchdogs back Iclusig, but with new warnings; Heart failure sales set to soar, thanks to Novartis drug;

@FiercePharma: Tops in FierceVaccines Thurs: Takeda appoints new vaccine development head as Novartis' Oswald heads for the door. Story | Follow @FiercePharma

@CarlyHFierce: Favorite PR of the morning so far: "The holiday stress lurking beneath the gingerbread." | Follow @CarlyHFierce

> European regulators backed continued use of Ariad's ($ARIA) leukemia drug Iclusig, albeit with strengthened warnings; the drug was briefly pulled in the U.S. last year, but put back on the market with restrictions to a small group of patients. Report

> Allergan ($AGN) paid $24 million to doctors and hospitals, the second-largest amount from any company in California, the new Open Payments database shows. Report

> Novartis ($NVS) worked out a new reimbursement deal with New Zealand to include new products for multiple sclerosis, COPD and leukemia, among others. Report

> Analysts figure that growth in drugs for heart failure will soar, largely fueled by a forthcoming treatment from Novartis. Report

Medical Device News

@FierceMedDev: Researchers implant brain-controlled prosthetic arm with sensation. Story | Follow @FierceMedDev

@VarunSaxena2: Hillary Clinton hedges on the device tax, says nation must weigh pros and cons. More | Follow @VarunSaxena2

@EmilyWFierce: $MDT sans José? Release | Follow @EmilyWFierce

@MichaelGFierce: With $RHHBY's Herceptin, green tea component doubles drug accumulation in cancer cells. Article | Follow @MichaelGFierce

> C2 Therapeutics raises $11.6M for esophageal ablation. More

> Medtronic reveals corporate shakeup pending close of Covidien deal. Story

Biotech News

@FierceBiotech: EuroBiotech Report: New U.K. biotech bags £15.5M, Forbion plans €200M fund, Serono strikes oncology deal. Report | Follow @FierceBiotech

@JohnCFierce: Regado's CEO steps down as the biotech limps forward. Story | Follow @JohnCFierce

@DamianFierce: Deal: $AUXL leaves $QLTI at the altar and accepts a $2.6B offer from $ENDP. More | Follow @DamianFierce

@EmilyMFierce: At Phila. conference, how a hospital successfully treated Ebola. Story via Philly.com | Follow @EmilyMFierce

> Prosensa heads to the FDA with its once-failed DMD treatment. Story

> Isis rolls into Phase III with an orphan drug as it waits on Biogen. More

> Novartis to shed three division heads in midst of Glaxo, Lilly deal prep. Chutes & Ladders

And Finally... Nebraska's biocontainment center is getting its first workout with the arrival of Ebola in the U.S. Report (sub. req.)

Suggested Articles

AbbVie and Allergan were already jumping through hoops for their merger before a new tax added hundreds of millions to the cost.

Avastin and Herceptin saw U.S. slowdown that's “not very pronounced” after bioisim launched, but Roche execs still warn of "a significant impact.…

Novo Nordisk, which recently completed a wastewater treatment plant for its massive U.S. API site, has made a gift of the $40 million facility.